Shamburg News · 8-K filed Nov 12, 2026, 4:07 PM EST

SELLAS Life Sciences Reports Q3 2026 Net Loss of $10.1 Million and $134.7 Million in Cash

SLS · SELLAS Life Sciences Group, Inc.

  • Earnings
  • Other event
  • Materiality: high

SELLAS Life Sciences Group reported a third-quarter 2026 net loss of $10.1 million, or $0.05 per basic and diluted share, compared with a net loss of $6.8 million, or $0.06 per share, in the third quarter of 2025. Research and development expenses rose to $7.0 million and general and administrative expenses to $4.3 million for the quarter. Cash and cash equivalents totaled approximately $134.7 million as of September 30, 2026, and the company provided a corporate update on its REGAL Phase 3 trial of GPS and its SLS009 programs.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001390478-26-000021.

Written from the filing by Shamburg Markets. Figures are as reported by the company.